Alto Neuroscience, Inc. Defined Contribution Plan, Cost
Alto Neuroscience, Inc. (ANRO) reported Defined Contribution Plan, Cost of $400.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-03-16
- Alto Neuroscience, Inc. defined contribution plan, cost for the quarter ending 2024-12-31 was $0.00.
- Alto Neuroscience, Inc. defined contribution plan, cost for the quarter ending 2024-09-30 was $100.00K, a 0.00% change year-over-year.
- Alto Neuroscience, Inc. defined contribution plan, cost for the quarter ending 2024-06-30 was $100.00K, a 0.00% change year-over-year.
- Alto Neuroscience, Inc. defined contribution plan, cost for the quarter ending 2024-03-31 was $100.00K, a 0.00% change year-over-year.
- Alto Neuroscience, Inc. defined contribution plan, cost for fiscal 2025 was $400.00K, a 33.33% increase from fiscal 2024.
- Alto Neuroscience, Inc. defined contribution plan, cost for fiscal 2024 was $300.00K, a 50.00% increase from fiscal 2023.
- Alto Neuroscience, Inc. defined contribution plan, cost for fiscal 2023 was $200.00K.
| Period end | Defined Contribution Plan, Cost 3 month | Defined Contribution Plan, Cost 6 month | Defined Contribution Plan, Cost 9 month | Defined Contribution Plan, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $400.00K 10-K · filed 2026-03-16 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $100.00K derived: sum of 2 quarters · filed 2026-03-16 | $200.00K derived: sum of 3 quarters · filed 2026-03-16 | $300.00K 10-K · filed 2026-03-16 |
| 2024-09-30 | $100.00K 10-Q · filed 2024-11-12 | $200.00K derived: sum of 2 quarters · filed 2024-11-12 | $300.00K 10-Q · filed 2024-11-12 | $300.00K derived: sum of 4 quarters · filed 2025-03-20 |
| 2024-06-30 | $100.00K 10-Q · filed 2024-08-13 | $200.00K 10-Q · filed 2024-08-13 | $200.00K derived: sum of 3 quarters · filed 2025-03-20 | $300.00K derived: sum of 4 quarters · filed 2025-03-20 |
| 2024-03-31 | $100.00K 10-Q · filed 2024-05-14 | $100.00K derived: sum of 2 quarters · filed 2025-03-20 | $200.00K derived: sum of 3 quarters · filed 2025-03-20 | $300.00K derived: sum of 4 quarters · filed 2025-03-20 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $100.00K derived: sum of 2 quarters · filed 2025-03-20 | $200.00K derived: sum of 3 quarters · filed 2025-03-20 | $200.00K 10-K · filed 2025-03-20 |
| 2023-09-30 | $100.00K 10-Q · filed 2024-11-12 | $200.00K derived: sum of 2 quarters · filed 2024-11-12 | $200.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $100.00K 10-Q · filed 2024-08-13 | $100.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $100.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |